AIM: To define the incidence and characteristics of latent autoimmune diabetes in adults (LADA). METHODS: We estimated the incidence of LADA by examining the incidence of Type 2 diabetes and calculating the proportion that were antibody positive. The incidence of Type 2 diabetes was calculated by analysis of computer records of 35 out of 36 general practices in Swansea. In addition, thirty-two practices participated in recruiting people with Type 2 diabetes to have glutamic acid decarboxylase (GAD) antibody testing. RESULTS: The crude proportion of Type 2 patients testing positive for GAD antibodies (GADA) was 4.0% (28/683). This figure did not change when we analysed only the practices that tested more than 60% of all eligible patients. In these practices, 79% (387/487) of all eligible patients were GADA tested and 14/387 [3.6% (95% confidence interval: 2.1-6.1%)] were classified as having LADA. This gives an incidence of LADA of 9 per 100,000 (95% confidence interval: 4.4-17.8 per 100,000) people per year registered with a general practitioner. Patients testing positive for GADA were more likely to have a lower body mass index, other antibodies, to present with acute symptoms and to have higher glycated haemoglobin. CONCLUSIONS: This is the first study of the incidence of LADA in primary care. People with LADA make up a significant proportion of people with apparent Type 2 diabetes. Patients with LADA are likely to be symptomatic, have poorer glycaemic control and have other autoimmune antibodies.
AIM: To define the incidence and characteristics of latent autoimmune diabetes in adults (LADA). METHODS: We estimated the incidence of LADA by examining the incidence of Type 2 diabetes and calculating the proportion that were antibody positive. The incidence of Type 2 diabetes was calculated by analysis of computer records of 35 out of 36 general practices in Swansea. In addition, thirty-two practices participated in recruiting people with Type 2 diabetes to have glutamic acid decarboxylase (GAD) antibody testing. RESULTS: The crude proportion of Type 2 patients testing positive for GAD antibodies (GADA) was 4.0% (28/683). This figure did not change when we analysed only the practices that tested more than 60% of all eligible patients. In these practices, 79% (387/487) of all eligible patients were GADA tested and 14/387 [3.6% (95% confidence interval: 2.1-6.1%)] were classified as having LADA. This gives an incidence of LADA of 9 per 100,000 (95% confidence interval: 4.4-17.8 per 100,000) people per year registered with a general practitioner. Patients testing positive for GADA were more likely to have a lower body mass index, other antibodies, to present with acute symptoms and to have higher glycated haemoglobin. CONCLUSIONS: This is the first study of the incidence of LADA in primary care. People with LADA make up a significant proportion of people with apparent Type 2 diabetes. Patients with LADA are likely to be symptomatic, have poorer glycaemic control and have other autoimmune antibodies.
Authors: Raffaella Buzzetti; Ernesto Maddaloni; Jason Gaglia; R David Leslie; F Susan Wong; Bernhard O Boehm Journal: Nat Rev Dis Primers Date: 2022-09-22 Impact factor: 65.038
Authors: Olufunmilayo O Adeleye; Anthonia O Ogbera; Olufemi Fasanmade; Olayinka O Ogunleye; Akinola O Dada; Ayotunde O Ale; Femi M Abatan Journal: Int Arch Med Date: 2012-08-15
Authors: Sinead Brophy; Helen Davies; Jeffrey W Stephens; Sarah L Prior; Mark Atkinson; Stephen Bain; Rhys Williams Journal: BMC Res Notes Date: 2010-11-22
Authors: Mark D Atkinson; Sinead Brophy; Stefan Siebert; Mike B Gravenor; Ceri Phillips; David V Ford; Kerina H Jones; Ronan A Lyons Journal: BMC Musculoskelet Disord Date: 2010-09-01 Impact factor: 2.362
Authors: Scott J Pilla; Ashok Balasubramanyam; William C Knowler; Mariana Lazo; David M Nathan; Xavier Pi-Sunyer; Jeanne M Clark; Nisa M Maruthur Journal: Autoimmunity Date: 2019-01-02 Impact factor: 2.815
Authors: Mohammed I Hawa; Hubert Kolb; Nanette Schloot; Huriya Beyan; Stavroula A Paschou; Raffaella Buzzetti; Didac Mauricio; Alberto De Leiva; Knud Yderstraede; Henning Beck-Neilsen; Jaakko Tuomilehto; Cinzia Sarti; Charles Thivolet; David Hadden; Steven Hunter; Guntram Schernthaner; Werner A Scherbaum; Rhys Williams; Sinead Brophy; Paolo Pozzilli; Richard David Leslie Journal: Diabetes Care Date: 2012-12-17 Impact factor: 19.112
Authors: Barbara Szepietowska; Anna Głębocka; Urszula Puch; Maria Górska; Małgorzata Szelachowska Journal: Arch Med Sci Date: 2012-07-04 Impact factor: 3.318